Ibrance 75 mg, 100 mg, 125 mg Capsules
PDF Leaflet Revision Date: 31 October 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of HR-positive, HER2-negative advanced or metastatic breast cancer.
Dosage (summary)
125 mg orally once daily with food for 21 days, followed by 7 days off.
Special Populations
- Elderly population
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy; contraindicated in breastfeeding.
Key Drug Interactions
- Strong CYP3A inhibitors
- Strong CYP3A inducers
Contraindications
- Hypersensitivity to palbociclib or excipients
Common side effects
- Neutropenia
- Infections
- Fatigue
- Nausea
- Stomatitis
Counselling Points
- Take with food.
- Do not chew or crush capsules.
- Report signs of infection or respiratory symptoms.
Serious warnings
- Neutropenia
- Interstitial lung disease/pneumonitis
- Infections
Important Disclaimer
The Ibrance 75 mg, 100 mg, 125 mg Capsules professional information leaflet below is the property of Pfizer Laboratories and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
